{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-21-050817","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2021-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.140661+00:00","generated_at":"2026-06-29T00:20:43.956568+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"OptimizeRx appoints Edward Stelmakh CFO/COO; Doug Baker transitions to EVP of finance","bullets":["Edward Stelmakh named CFO/COO effective Oct 11, 2021; Doug Baker becomes EVP of finance and accounting.","Stelmakh's annual base salary set at $425,000; target bonus 50% of base; one-time equity grant valued at $3.0 million.","Stelmakh brings 30+ years pharma experience, most recently as CFO/COO at Otsuka America Pharmaceuticals.","Severance includes 12 months base salary if terminated without cause, plus COBRA coverage for 12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-21-050817","json":"https://secwatch.observer/filing/0001213900-21-050817.json","markdown":"https://secwatch.observer/filing/0001213900-21-050817.md","text":"https://secwatch.observer/filing/0001213900-21-050817.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000121390021050817/0001213900-21-050817-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000121390021050817/ea148140-8k_optimizerx.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T00:20:43.956568+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0df455abbf","claim":"Douglas P. Baker changed role as EVP of finance and accounting at OptimizeRx Corp.","evidence_excerpt":"On September 24, 2021, the Company and Douglas P. Baker, the Company’s current Chief Financial Officer, agreed that Mr. Baker will transition into the position of EVP of finance and accounting.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390021050817/0001213900-21-050817-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"EVP of finance and accounting"}],"fact_type":"executive_change"},{"claim_id":"b8a87dddd5","claim":"Edward Stelmakh was appointed as Chief Financial Officer/Chief Operations Officer at OptimizeRx Corp.","evidence_excerpt":"On September 30, 2021, OptimizeRx Corporation (the “Company”) announced that Edward Stelmakh has been appointed to serve as the Company’s Chief Financial Officer/Chief Operations Officer, effective as of October 11, 2021 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390021050817/0001213900-21-050817-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer/Chief Operations Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}